Turning Point Therapeutics is keen not to become a one-trick pony focused on repotrectinib, and a late-breaker at the EORTC-NCI-AACR symposium on Saturday helped build its case as a broad player in targeted therapy for cancers driven by specific genetic mutations.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,